AstraZeneca: Cancer Drug Challenges
The Tech Times website reports that the biopharmaceutical company AstraZeneca has announced its decision to release the preclinical data from more than 50 of its medicines as part of the open innovation non-profit biology project called DREAM Challenges, which aims to find drug combinations that can potentially treat cancer. AstraZeneca’s decision is aimed at helping advance research into combination therapy. The company said that its move to make a large data set accessible to outside researchers shows that it is committed to open innovation.
Click here to read the full article.